Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global leader in the pharmaceutical, medical device, and over-the-counter product industries, primarily focusing on the therapeutic areas of eye health, gastroenterology, and dermatology. The company is dedicated to advancing global health through innovation and efficient healthcare solutions.
With approximately 22,000 employees worldwide, Bausch Health operates in around 100 countries. The company's core business is organized into five segments: Salix Pharmaceuticals, International, Solta Medical, Diversified Products, and Bausch + Lomb, with the Bausch + Lomb segment generating the highest revenue. Bausch Health consistently delivers on its commitments to quality health care outcomes and customer focus.
Recent achievements include significant progress in the development of Amiselimod, a promising new treatment for ulcerative colitis, and the expansion of public drug plan listings for UCERIS® (budesonide) aerosol foam in multiple Canadian provinces. Additionally, Bausch Health has launched an awareness campaign for XIFAXAN®, an FDA-approved medication for reducing the risk of overt hepatic encephalopathy recurrence.
Financially, Bausch Health reported strong performance in the first quarter of 2024, with revenues of $2.15 billion, marking a 11% increase compared to the prior year. The company continues to strengthen its balance sheet while advancing its R&D pipeline and executing commercial strategies for global growth.
Bausch Health remains focused on protecting its intellectual property, as evidenced by recent litigation efforts to defend the XIFAXAN® franchise. The company is also committed to fostering partnerships and collaborations to enhance its product offerings and reach.
For more information, visit www.bauschhealth.com.
Bausch Health Companies (NYSE/TSX: BHC) announces the opening of applications for the 2022 Aspire Higher Scholarship program, targeting students affected by dermatologic conditions. The program, active since 2013, will award nine scholarships of up to $10,000 each to aid educational pursuits. Applicants must submit recommendations and an essay detailing their experiences. This initiative has granted 60 scholarships totaling $828,000 over the years. Applications are open until May 31, 2022, with recipients announced in summer 2022.
On March 1, 2022, Salix Pharmaceuticals, part of Bausch Health (NYSE: BHC), partnered with the Colon Cancer Coalition to promote colorectal cancer screening awareness. The initiative, known as the Faces of Blue campaign, will share patient stories to encourage screenings, especially following the U.S. Preventive Services Task Force's guideline lowering the screening age to 45. This change affects approximately 45 million Americans now eligible for early detection screenings. Salix aims to enhance education and outreach through new resources and social media partnerships.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced participation in the J.P. Morgan Global High Yield & Leveraged Finance Conference on March 1, 2022, at 9:15 a.m. ET. Key executives, including CFO Sam Eldessouky and SVP Arthur J. Shannon, will represent the company. Bausch Health focuses on improving health with a range of products in eye health, gastroenterology, and dermatology. The company's commitment to advancing global health and innovative solutions is highlighted.
Bausch Health reported its fourth-quarter and full-year 2021 financial results, revealing revenues of $2.196 billion for Q4 and $8.434 billion for the full year, up 5% from 2020. Despite a net income of $69 million in Q4, the company faced a full-year net loss of $948 million. Noteworthy achievements include the successful launch of four new products and progress in IPO preparations for Bausch + Lomb and Solta. However, cash generated from operations dropped significantly by 94% in Q4, emphasizing operational challenges.
Bausch Health Companies (NYSE/TSX: BHC) announced the U.S. launch of the OraFit™ custom clear aligner system on Feb. 22, 2022, aimed at correcting malocclusion. This system features a three-layer design with high-performance materials, providing a comfortable and aesthetically pleasing option for patients. With malocclusion affecting approximately 66% of individuals in the U.S., OraFit™ offers dentists a new solution that promotes patient acceptance and compliance. It also integrates a user-friendly online resource for dental professionals to streamline case submissions.
Bausch Health and its gastroenterology division, Salix Pharmaceuticals, have announced the opening of the 2022 Salix Gastrointestinal Health Scholars Program. This initiative will award scholarships of up to $10,000 to 10 students living with gastrointestinal diseases who are pursuing higher education. The application period runs until May 15, 2022, with recipient notifications expected in the summer. The program includes various awards categories, emphasizing the company’s commitment to supporting students.
KBRA has published its Fourth-Quarter 2021 U.S. Bank Compendium, offering insights into the U.S. banking sector's performance and credit metrics for the quarter. The report includes analyses of actions by larger banks regarding overdraft fees and features a quarterly ESG Bulletin. Notable highlights include summaries of publicly traded U.S. banks, key performance metrics, and data on top deposit franchises. Atlantic Union Bankshares Corporation (NASDAQ: AUB) is rated BBB+ with a positive outlook. For detailed insights, the full report is accessible online.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced its subsidiary, Solta Medical Corporation, has filed a registration statement for a proposed IPO of its common shares. The share price and offering size are yet to be determined. Solta aims to list on the Nasdaq under the symbol 'SLTA'. Bausch Health has completed internal steps for launching both Solta and Bausch + Lomb IPOs, pending regulatory approvals. Major investment firms, including Goldman Sachs and Morgan Stanley, are managing the offering.
Bausch Health Companies (NYSE/TSX: BHC) will announce its financial results for Q4 and full-year 2021 on February 23, 2022. A conference call is scheduled for 8:00 a.m. ET to discuss the results and provide a business update. Investors can access the call through the company’s Investor Relations website. Bausch Health focuses on improving lives through its health care products, primarily in eye health, gastroenterology, and dermatology.
Bausch + Lomb partners with Prevent Blindness for the seventh year during AMD Awareness Month, launching a campaign aimed at educating the public on Age-Related Macular Degeneration (AMD), which affects 16 million adults in the U.S. The initiative aims to raise awareness and funds, contributing $1 for each social media interaction, with a goal of $50,000. Bausch + Lomb's president emphasized the importance of eye examinations, as early diagnosis is crucial. The company also plans to release its Visionary Report to identify AMD education gaps.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
What are the primary areas of focus for Bausch Health?
How many employees does Bausch Health have?
In how many countries does Bausch Health operate?
What is Bausch Health's largest revenue-generating segment?
What recent product development has Bausch Health achieved?
What financial performance did Bausch Health report for Q1 2024?
How is Bausch Health protecting its intellectual property?
Where can I find more information about Bausch Health?
What recent public drug plan listings has Bausch Health achieved in Canada?
Who is the brand ambassador for the XIFAXAN® awareness campaign?
